Ceftaroline-heteroresistant staphylococcus aureus

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 6, 2014, Pages 3133-3136

  Saravolatz, Stephanie N ^a   Martin, Hayley ^a   Pawlak, Joan ^a   Johnson, Leonard B ^a   Saravolatz, Louis D ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFTAROLINE; DAPTOMYCIN; LINEZOLID; VANCOMYCIN; ANTIINFECTIVE AGENT; CEPHALOSPORIN DERIVATIVE;

ARTICLE; BACTERIUM ISOLATE; BROTH DILUTION; CEFTAROLINE HETERORESISTANT STAPHYLOCOCCUS AUREUS; COLONY FORMING UNIT; DAPTOMYCIN NONSUSCEPTIBLE STAPHYLOCOCCUS AUREUS; HETERORESISTANT VANCOMYCIN INTERMEDIATE STAPHYLOCOCCUS AUREUS; HUMAN; IN VITRO STUDY; LINEZOLID NONSUSCEPTIBLE STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM BACTERICIDAL CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MULTIPLEX POLYMERASE CHAIN REACTION; NONHUMAN; PRIORITY JOURNAL; PULSED FIELD GEL ELECTROPHORESIS; STAPHYLOCOCCUS AUREUS; VANCOMYCIN INTERMEDIATE STAPHYLOCOCCUS AUREUS; ANTIBIOTIC RESISTANCE; DRUG EFFECTS; MICROBIAL SENSITIVITY TEST; STAPHYLOCOCCUS INFECTION;

ANTI-BACTERIAL AGENTS; CEPHALOSPORINS; DAPTOMYCIN; DRUG RESISTANCE, BACTERIAL; ELECTROPHORESIS, GEL, PULSED-FIELD; HUMANS; LINEZOLID; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; VANCOMYCIN; VANCOMYCIN RESISTANCE;

EID: 84901282915     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02685-13     Document Type: Article

References (15)

1. Saravolatz LD, Stein GE, Johnson LB. 2011. Ceftaroline: a novel cephalosporin with activity against methicillin-resistant Staphylococcus aureus. Clin. Infect. Dis. 52:1156-1163. http://dx.doi.org/10.1093/cid/cir147.
2. Clinical and Laboratory Standards Institute. 2013. Performance standards for antimicrobial susceptibility testing. Twenty-third informational supplement. M100-S23. Clinical and Laboratory Standards Institute, Wayne, PA.
3. Saravolatz LD, Pawlak J, Johnson LB. 2012. In vitro susceptibilities and molecular analysis of vancomycin-intermediate and vancomycinresistant Staphylococcus aureus isolates. Clin. Infect. Dis. 55:582-586. http://dx.doi.org/10.1093/cid/cis492.
4. Deresinski S. 2009. Vancomycin heteroresistance and methicillinresistant Staphylococcus aureus. J. Infect. Dis. 199:605-609. http://dx.doi.org/10.1086/ 596630.
5. Zhang K, McClure J, Elsayed S, Louie T, Conly JM. 2005. Novel multiplex PCR assay for characterization and concomitant subtyping of staphylococcal cassette chromosome mec types I to V in methicillinresistant Staphylococcus aureus. J. Clin. Microbiol. 43:5026-5033. http://dx.doi.org/10.1128/JCM.43.10. 5026-5033.2005.
6. McDougal LK, Steward CD, Killgore GE, Chaitram JM, McAllister SK, Tenover FC. 2003. Pulsed-field gel electrophoresis typing of oxacillinresistant Staphylococcus aureus isolates from the United States: establishing a national database. J. Clin. Microbiol. 41:5113-5120. http://dx.doi.org/10.1128/JCM.41.11. 5113-5120.2003.
7. Vidaillac C, Leonard SN, Rybak MJ. 2009. In vitro activity of ceftaroline against methicillin-resistant Staphylococcus aureus and heterogeneous vancomycin-intermediate S. aureus in a hollow fiber model. Antimicrob. Agents Chemother. 53:4712-4717. http://dx.doi.org/10.1128/AAC.00636-09.
8. Meletis G, Tzampaz E, Sianou E, Tzavaras I, Sofianou D. 2011. Colistin heteroresistance in carbapenemase-producing Klebsiella pneumoniae. J. Antimicrob. Chemother. 66:946-947. http://dx.doi.org/10.1093/jac/dkr007.
9. Boyle-Vavra S, Berke SK, Lee JC, Daum RS. 2000. Reversion of the glycopeptide resistance phenotype in Staphylococcus aureus clinical isolates. Antimicrob. Agents Chemother. 44:272-277. http://dx.doi.org/10.1128/AAC.44.2. 272-277.2000.
10. Liu C, Chambers HF. 2003. Staphylococcus aureus with heterogeneous resistance to vancomycin: epidemiology, clinical significance, and critical assessment of diagnostic methods. Antimicrob. Agents Chemother. 47: 3040-3045. http://dx.doi.org/10.1128/AAC.47.10.3040-3045.2003.
11. Khatib R, Jinson J, Musta A, Sharma M, Fakih MG, Johnson LB, Riederer K, Shemes S. 2011. Relevance of vancomycin-intermediate susceptibility and heteroresistance in methicillin-resistant Staphylococcus aureus bacteraemia. J. Antimicrob. Chemother. 66:1594-1599. http://dx.doi.org/10.1093/jac/dkr169.
12. Smith TL, Pearson ML, Wilcox KR, Cruz C, Lancaster MV, Robinson-Dunn B, Tenover FC, Zervos MJ, Band JD, White E, Jarvis WR. 1999. Emergence of vancomycin resistance in Staphylococcus aureus. N. Engl. J. Med. 340:493-501. http://dx.doi.org/10.1056/NEJM199902183400701.
13. Hanaki H, Kuwahara-Arai K, Boyle-Vavra S, Daum RS, Labischinski H, Hiramatsu K. 1998. Activated cell-wall synthesis is associated with vancomycin resistance in methicillin-resistant Staphylococcus aureus clinical strains Mu3 and Mu50. J. Antimicrob. Chemother. 42:199-209. http://dx.doi.org/10.1093/jac/ 42.2.199.
14. Mendes RE, Tsakris A, Sader HS, Jones RN, Biek D, McGhee P, Appelbaum PC, Kosowksa-Shick K. 2012. Characterization of methicillin-resistant Staphylococcus aureus displaying increased MICs of ceftaroline. J. Antimicrob. Chemother. 67:1321-1324. http://dx.doi.org/10.1093/jac/dks069.
15. Werth BJ, Steed ME, Kaatz GW, Rybak MJ. 2013. Evaluation of ceftaroline activity against heteroresistant vancomycin-intermediate Staphylococcus aureus and vancomycin-intermediate methicillin-resistant S. aureus strains in an in vitro pharmacokinetic/pharmacodynamics model: exploring the "seesaw effect." Antimicrob. Agents Chemother. 57:2664-2668. http://dx.doi.org/10. 1128/AAC.02308-12.